首頁 › 乳癌 › 康乃狄克 › Bridgeport
Bridgeport, CT 的 乳癌 臨床試驗
21 項針對 乳癌 的研究正在 Bridgeport（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Stony Brook University Medical Center, Stony Brook · 距離 18 英里
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
招募中3 期
- Stony Brook University-Cancer Center ( Site 0034), Stony Brook · 距離 18 英里
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Stony Brook · 距離 18 英里
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
招募中3 期
- Smilow Cancer Hospital Care Center - Trumbull, Trumbull · 距離 4 英里
- Smilow Cancer Hospital Care Center - Fairfield, Fairfield · 距離 5 英里
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
招募中
- Stony Brook Cancer Center, Stony Brook · 距離 18 英里
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
招募中1/2 期
- Stony Brook University Hospital, Stony Brook · 距離 18 英里
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
招募中3 期
- Stony Brook University Medical Center, Stony Brook · 距離 18 英里
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- Stony Brook University Cancer Center, Stony Brook · 距離 18 英里
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
招募中3 期
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Port Jefferson Station2), Port Jefferson Station · 距離 19 英里
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(Port Jefferson Station1), Port Jefferson Station · 距離 19 英里
- New York Cancers & Blood Specialists, Port Jefferson Station · 距離 19 英里
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 距離 4 英里
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 距離 5 英里
- 還有 1 項
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
招募中2 期
- Stony Brook Cancer Center, Stony Brook · 距離 18 英里
ATEMPT 2.0: Adjuvant T-DM1 vs TH
招募中2 期
- Smilow Cancer Hospital Care center at Trumbull, Trumbull · 距離 4 英里
- Smilow Cancer Hospital Care center at Fairfield, Fairfield · 距離 5 英里
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
招募中1 期
- New York Cancer and Blood Specialists, Port Jefferson Station · 距離 19 英里
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
招募中3 期
- Stony Brook University Cancer Center, Stony Brook · 距離 18 英里
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
招募中3 期
- Smilow Cancer Hospital - Fairfield, Fairfield · 距離 5 英里
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 距離 4 英里
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 距離 5 英里
- Stony Brook University Medical Center, Stony Brook · 距離 18 英里
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
招募中觀察性研究
- Stony Brook Medicine, Stony Brook · 距離 18 英里
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
招募中早期第 1 期
- Stony Brook Breast Center, Stony Brook · 距離 18 英里
Definitive Radiation Therapy for Inoperable Breast Cancer
招募中
- Stony Brook University Cancer Center, Stony Brook · 距離 18 英里
Definitive Radiation for High-Risk Spine Metastases
招募中2 期
- Stony Brook University Hospital, Stony Brook · 距離 18 英里
CtDNA Based MRD Testing for NAC Monitoring in TNBC
招募中觀察性研究
- Stony Brook University Cancer Center, Stony Brook · 距離 18 英里
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Bridgeport 的其他研究
- 非小細胞肺癌14 項研究
- 肺癌13 項研究
- 急性髓系白血病12 項研究
- 心血管疾病9 項研究
- 癌症（所有類型）8 項研究
- 頭頸部鱗狀細胞癌8 項研究
- 轉移性癌症7 項研究
- 心臟衰竭7 項研究
- 腦動脈瘤6 項研究
- 多發性骨髓瘤6 項研究
- 前列腺癌6 項研究
- 卵巢癌5 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。